Leslie Williams is a member of The Capital Network’s Board of Directors.
From this original post by Mass High Tech.
Born from research in Australia, new Cambridge startup ImmusanT Inc. has launched to commercialize a therapy that aims to treat celiac disease like a simple allergy with regular injections of a therapy.
According to Leslie J. Williams, founder, president and CEO of ImmusanT, what attracted her to the core concepts behind the company was “the science – the simplicity and the elegance of the science.” That science came from Nexpep Pty. Ltd., based in Melbourne, Australia, which had been founded by Bob Anderson, a gastroenterologist and an expert in immunology and clinical management of celiac disease at The Walter and Eliza Hall Institute of Medical Research.
Williams was contacted by Anderson when he was in Melbourne’s sister city of Boston doing a lecture tour, as someone who had been recommended to him for her expertise on bringing Nexpep into the U.S. market. What was planned to be a one hour lunch turned into three, Williams said, and she and Anderson began plans to make Nexpep an American company.
That led to the founding of ImmusanT in December, which then acquired the assets of Nexpep after landing an unspecified amount of seed funding from “high net worth individuals,” Williams said. She did say that the seed funding could possibly go to as high as $1 million, before the company would need to land a planned Series A venture capital round.
Read the rest of this entry →